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Abstract
The RB and p53 tumor suppressors are mediators of DNA damage response, and compound inactivation of RB and p53 is a
common occurrence in human cancers. Surprisingly, their cooperation in DNA damage signaling in relation to
tumorigenesis and therapeutic response remains enigmatic. In the context of individuals with heritable retinoblastoma,
there is a predilection for secondary tumor development, which has been associated with the use of radiation-therapy to
treat the primary tumor. Furthermore, while germline mutations of the p53 gene are critical drivers for cancer predisposition
syndromes, it is postulated that extrinsic stresses play a major role in promoting varying tumor spectrums and disease
severities. In light of these studies, we examined the tumor suppressor functions of these proteins when challenged by
exposure to therapeutic stress. To examine the cooperation of RB and p53 in tumorigenesis, and in response to therapy-
induced DNA damage, a combination of genetic deletion and dominant negative strategies was employed. Results indicate
that loss/inactivation of RB and p53 is not sufficient for cellular transformation. However, these proteins played distinct roles
in response to therapy-induced DNA damage and subsequent tumorigenesis. Specifically, RB status was critical for cellular
response to damage and senescence, irrespective of p53 function. Loss of RB resulted in a dramatic evolution of gene
expression as a result of alterations in epigenetic programming. Critically, the observed changes in gene expression have
been specifically associated with tumorigenesis, and RB-deficient, recurred cells displayed oncogenic characteristics, as well
as increased resistance to subsequent challenge with discrete therapeutic agents. Taken together, these findings indicate
that tumor suppressor functions of RB and p53 are particularly manifest when challenged by cellular stress. In the face of
such challenge, RB is a critical suppressor of tumorigenesis beyond p53, and RB-deficiency could promote significant cellular
evolution, ultimately contributing to a more aggressive disease.
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Introduction
The response to genotoxic stress is a critical event that has broad
implications to cancer. It is well appreciated that a number of
environmental carcinogens act through the induction of DNA
damage to promote tumor initiation [1,2]. For example, Aflatoxin
B1 elicits oxidative damage and is a key etiological factor for
hepatocellular carcinoma [3], and exposure to solar radiation is a
key risk factor for skin cancer [4]. While genotoxic agents are
strongly linked to tumorigenesis, the cytotoxic effect of DNA
damage is also a critical facet of cancer therapy. In fact, the majority
of human tumors are treated using agents that are genotoxic
compounds. A major caveat of such therapies is the possibility of
inducing secondary primary malignancies, or exacerbating existing
disease by promoting genomic instability or facilitating selection of
aggressive, therapy-resistant forms of disease [5]. Clearly, under-
standing genetic alterations that influence these responses is critical
for efficacious cancer treatment.
The retinoblastoma tumor suppressor (RB) is a regulator of the
cell cycle that is functionally inactivated in a variety of human
cancers [6,7,8]. RB functions as a negative regulator of a
transcriptional program that is mediated by E2F transcription
factors [9,10]. Transcriptional targets of RB include genes
involved in diverse processes, including DNA replication, cell
cycle progression, DNA damage response, and apoptosis
[11,12,13]. Correspondingly, the deletion of RB leads to the
deregulation of these target genes in many model systems [14].
An important consequence of gene deregulation through RB
loss is the propensity to facilitate bypass of the canonical DNA
damage checkpoints that inhibit G1 and S-phase progression
[15,16]. This function of RB is similar to that of the p53 tumor
suppressor [17,18,19,20]. While there is evidence that RB and p53
function in related/partially overlapping pathways to modify cell
cycle checkpoints, this point remains unresolved and is likely
modified by discrete forms of DNA damage. Importantly, many
tumors display disruption of both tumor suppressor pathways,
suggesting intrinsic cooperation [21,22,23]. One basis for this
cooperation is that while RB deficiency is associated with
enhanced cell death, p53 deficiency facilitates cell survival
[17,18,19,24].
How RB and p53 cooperate in DNA damage signaling in
relation to tumorigenesis and therapeutic response is not
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models, RB deficiency was associated with enhanced sensitivity to
cytotoxic therapy [8,25,26,27]. However, increased sensitivity in
such models did not lead to durable response, and recurrence can
contribute to therapy-resistance. In the context of individuals with
heritable retinoblastoma, there is a strong predilection for
secondary tumor development [28,29,30]. Particularly, such
secondary tumor development has been closely associated with
the use of radiation-therapy to treat the primary retinoblastoma
[28,29,31]. Similarly, while germline mutations of p53 are major
drivers for cancer predisposition syndromes, identical mutations
have been shown to result in widely varying tumor spectrums and
severities in different patients [32]. It is postulated that extrinsic
stresses (either environmental or therapy-induced) play a major
role in promoting secondary ‘‘hits’’ that can lead to higher cancer
predisposition [33,34].
In light of these studies, we questioned whether the combined
loss of RB and p53 is sufficient to drive tumorigenesis, or if the
tumor suppressor functions of these proteins are only truly
manifest when challenged by exposure to therapeutic stress. Our
findings indicate that loss of RB and p53 alone is not sufficient for
transformation. However, these proteins played distinct roles in
the response to therapy-induced damage, and interestingly, RB
was observed to be a critical modulator of DNA damage response
and senescence, irrespective of p53 status. Consequently, RB
deficiency promoted significant cellular evolution, ultimately
resulting in tumorigenesis and enhanced therapeutic resistance.
Materials and Methods
Isolation of Primary Rb
loxP/loxP Mouse Adult Fibroblasts
(MAFs) and Cell Culture
Primary mouse adult fibroblasts (MAFs) were isolated from
floxed Rb (Rb
loxP/loxP) mice and cultured as previously described
[16]. Rb
loxP/loxP MAFs were then subcultured in DMEM
containing 10% fetal bovine serum supplemented with 100 U/
mL penicillin/streptomycin and 2 mM L-glutamine at 37uCi n
5% CO2. All animal experiments were conducted in accordance
with the NIH Guide for Care and Use of Laboratory Animals and
were approved by the Thomas Jefferson University Institutional
Animal Care and Use Committee.
Viral Infections
Cells were infected with adenoviral constructs expressing green
fluorescent protein (GFP) or GFP and Cre recombinase (GFP-
Cre), with an infection efficiency of 90–95% as determined by
GFP immunofluorescence. Recombination at the Rb locus of
Rb
loxP/loxP MAFs was confirmed by PCR as previously described
[35]. GFP MAFs and GFP-Cre MAFs were infected with
retrovirus encoding LXSN or LXSN-p53DD, selected, and pooled
for characterization as previously described [26].
Immunoblot Analysis
Total cell lysates were resolved by SDS-PAGE and transferred
to Immobilon-P membrane (Millipore, Bedford, MA). Proteins
were detected using the following antibodies: from Santa Cruz
Biotechnology- lamin B (M-20), MCM7 (141.2), Cyclin A (C-19),
PCNA (PC10), p21 (C-19), phospho-ERK (E-4), ERK (K-23);
from Novacastra Ltd.- p53 (CM5); from Neomarkers- Cyclin D1
(Ab-3).
Cell Growth Analysis
1.5610
5 cells were seeded (Day 0), and every 24 h, cell numbers
were counted using trypan blue exclusion. For cisplatin (CDDP)
treatments, cells were treated 24 h after seeding, and plates were
stained with 1% crystal violet at the indicated time points.
Anchorage independent growth was facilitated through plating
cells into non-coated Petri dishes. For 5-aza-29-deoxycytidine (5-
aza-dC) (Sigma-Aldrich, St. Louis, MO) treatments, cells were
initially treated with 5 mM 5-aza-dC for 24 h, then subsequently
treated for 5 days with 1 mM 5-aza-dC.
BrdU Incorporation/Flow Cytometry
Cells were treated with CDDP (4 and 8 uM), Etoposide (1 uM),
Camptothecin (5 uM), or Mitomycin C (2 uM) for 24 h, or CDDP
(0.5 uM) up to 96 h, labeled with BrdU for 1 h, and processed for
flow cytometry as previously described [35].
b-galactosidase Assay
Cells were treated with CDDP (0.5 uM) for 48 h, and stained
for b-galactosidase (b-gal) activity using a Senescence b-gal
Staining Kit (Cell Signaling Technology, Danvers, MA). b-gal-
positive cells were quantified and displayed as fold-increase in
expression over untreated cells.
Foci Formation
Cells were treated with CDDP (1 uM) for 24 h, allowed to
recover in fresh media lacking CDDP, and stained with 1% crystal
violet two weeks post-treatment. Foci formation was quantified by
measuring the relative intensity of staining using ImageJ 1.41
software. Foci formation recovery assays were preformed with six
independently treated cell populations.
Microarray Analysis
RNA was harvested using TRIzol (Invitrogen, Carlsbad, CA)
according to the manufacturer’s suggested protocols and quantified
on a Nanodrop ND-100 spectrophotometer. RNA quality was
assessed by analysis on an Agilent 2100 bioanalyzer (Agilent, Palo
Alto, CA). Two micrograms of total RNA from each cell type was
used for Affymetrix one-cycle target labeling as recommended by
the manufacturer (Affymetrix, Santa Clara, CA). Each Affymetrix
GeneChip for Mouse Genome430 2.0was hybridized for 16 h with
biotin-labeled fragmented cRNA (10 mg) in 200 mL of hybridization
cocktail according to Affymetrix protocol. Arrays were washed and
stained using GeneChip Fluidic Station 450, and hybridization
signals were amplified using antibody amplification with goat IgG
(Sigma-Aldrich, St. Louis, MO) and anit-streptavidin biotinylated
antibody. Chips were scanned on an Affymetrix GeneChip Scanner
3000 using GeneChip Operating Software verson 3.0. Microarray
normalization was performed by computing the Robust Multichip
Average(RMA)expressionmeasure[PMID:12582260].Significant
genes changes were determined using Significance Analysis of
Micorarrays (SAM) [PMID: 11309499] in the TM4 MultiExperi-
ment Viewer (MeV) software package [PMID: 12613259].
Significant changes in gene expression were determined using a
1.5-fold cut-off in expression change and a FDR of ,25%.
Microarray analyses were performed on at least two independently
generated (naı ¨ve or recurred) cell populations. The complete
microarray gene list is included in Table S1. All microarray data
are MIAME compliant and have been deposited in NCBI’s Gene
Expression Omnibus (GEO). Raw data is accessible through GEO
Series accession number GSE18395.
Chromosome locations for the Mouse Genome 430 2.0 probe
sets were extracted from the Mouse430_2 annotation file release
29, dated 7/1/2009, available from the Affymetrix website.
Chromosome locations and fold-change values for the 1176
significant probe sets (,25% FDR and 1.5 fold-change) were
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function of chromosome position.
RT-PCR
RNA was harvested from cell cultures using TRIzol (Invitrogen,
Carlsbad, CA) according to the manufacturer’s suggested protocol.
Superscript reverse transcriptase (Invitrogen, Carlsbad, CA) and 5 g of
total RNA were used to generate cDNAs with random hexamer
primers. PCR was carried out using the following primers: 59-
GTCACAGACCTGCAGTGGCTCAT-39 and 59-ATCTTGGAG-
TAAGACAGTGGTCC-39 (Lumican), 59-GCCACAACGTGGGC-
TACAA-39 and 59-ACCTCTGCCATGGTCTCGTG-39 (Sfrp1), 59-
ATGGAAACCCTTTGTAAAAATGACT-39 and 59-TCTTGCT-
CTTTGTCTCCAGGATGAT-39 (Sfrp2), 59-GAAGGGCCAGT-
GTGAAAGTG-39 and 59-GGGCAGGATTGTTGGTTGAA-39
(Clusterin), 59-GTTGCCTTCGATGGGAAAAAG-39 and 59-
TGGGACAGTCGTCTCTCTGGA-39 (Gpr149), 59-CAGACTC-
CAAAGGACATCGCAA-39 and 59-GTCAAAGGGTGACCCAG-
GAA-39 (Pla2g7), 59-ATCTTCCAGGAGCGAGACCCCA-39 and
59-TCCACAATGCCAAAGTTGTCATGG-39 (GAPDH). PCR
conditions were as follows: denaturation at 94uC for 30 s, annealing
at 58uC for 30 s, and elongation at 72uC for 30 s for all reactions, with
30 cycles for SFRP1, Gpr149 and GAPDH, and 36 cycles for
Lumican, SFRP2, Clusterin and Pla2g7.
Immunofluorescence
For phalloidin staining, cells were plated on coverslips in 6-well
dishes, fixed in 3.7% formaldehyde, and processed according to
the manufacturer’s protocol (Invitrogen Molecular Probes,
Carlsbad, CA). For CDDP adduct detection, cells were plated
on coverslips, treated with 8 mM CDDP for 24 h, fixed in 3.7%
formaldehyde, and processed as previously described [36].
Xenografts
Tumors were grown as xenografts in 6-week-old to 8-week-old
female athymic nude mice (Harlan Sprague-Dawley, Inc.) by
subcutaneous flank injection of 2610
6 cells in 150 mLo fp h o s -
phate-buffered saline solution mixed with 50 mLo fM a t r i g e l( B D
Biosciences, Bedford, MA). Once palpable, tumors were measured
with calipers every 7 days, and tumor volume was calculated as
v=p(width
26length)/6. Xenograft tumor formation assays were
performed in two cohorts of nude mice with two independently
generated(naı ¨veorrecurred)cellpopulations.Allanimalexperiments
were conducted in accordance with the NIHGuide forCareand Use
of Laboratory Animals and were approved by the Thomas Jefferson
University Institutional Animal Care and Use Committee.
H&E Tissue Staining
Tissue from xenografts was fixed in 10% neutral buffered
formalin (NBF), paraffin-embedded, and cut into 5 um sections.
Sections were stained with H&E using standard techniques.
Statistical Analysis
All statistical analyses were performed with GraphPad Prism
(GraphPad Prism Software, Inc.) unless otherwise indicated. P
values were calculated by performing Student’s T-Tests.
Results
RB Mediates Acute Cell Cycle Arrest in Response to
Therapy, Independent of p53 Status
To examine the cooperation of RB and p53 dysfunction in
response to therapy-induced damage, primary adult fibroblasts
(MAFs) were isolated from Rb
loxp/loxp mice and subjected to viral
transduction targeting the Rb gene and/or the p53 protein.
Specifically, MAFs were infected with adenovirus expressing either
a GFP vector or GFP and Cre recombinase, which results in the
deletion of exon 19 of Rb (Figure 1A, left panel). This
recombination event has been established to result in the loss of
RB protein expression [35,37]. Additionally, RB-proficient and
RB-deficient MAFs were infected with an empty retroviral vector,
LXSN, or a retroviral vector expressing an N-terminally truncated
dominant-negative form of murine p53, LXSN-p53DD (Figure 1A,
right panel). Similar to previous reports, cells infected with LXSN-
p53DD displayed an accumulation of endogenous p53 (Figure 1A,
right panel, lanes 5–8). However, elevated levels of endogenous
p53 did not result in up-regulation of p21 in the presence of the
DNA damaging compound cisplatin (CDDP) (Figure 1A, right
panel, compare lanes 2 and 4 to lanes 6 and 8), indicating that the
response of the p53 pathway to DNA damage had been
compromised [26,38]. Introduction of LXSN-p53DD into MAFs
resulted in increased levels of DNA replication (Figure 1B), as well
as enhanced cell proliferation (Figure 1C) when compared to
control cell populations. Interestingly, RB and p53 deficiency
resulted in additive effects on proliferation in extended culture,
resulting in a .2-fold growth advantage as compared to cells
harboring a single tumor suppressor deficiency (Figure 1C).
Previous studies have shown that loss of RB or p53 results in
bypass of the G1/S checkpoint normally triggered by DNA
damage [15,16]. To examine the cooperation of RB and p53
deficiency in bypass of therapy-induced damage, cells were
challenged with cisplatin (CDDP) for 24 hours, and DNA
replication was monitored by BrdU incorporation (Figure 1D).
RB-proficient cells displayed a significant decrease in DNA
replication upon exposure to CDDP, independent of p53 status.
In contrast, loss of RB resulted in bypass of DNA damage-
mediated cell cycle arrest, though some sensitivity is observed at
higher concentrations (Figure 1D). These data suggest that while
both the RB and p53 pathways play a role in regulating normal
cell proliferation, RB function is dominant for cell cycle
checkpoint response to therapy-induced damage.
RB Status Is Critical for Maintaining Cell Cycle Arrest and
Initiating Cellular Senescence in the Absence of a
Functional p53 Pathway
To mimic clinically relevant exposure to therapies, such as
CDDP, we next monitored the ability of the cells to proliferate
under continuous, low-dose (0.5 uM) CDDP treatment. Levels of
DNA replication in RB-proficient p53DD cells decreased by
,70% in the presence CDDP over the course of 4 days (Figure 2A,
top and left panel). In contrast, levels of DNA replication were
diminished by only ,20% in RB-deficient p53DD cells,
confirming the importance of RB in not only initiating cell cycle
checkpoints while p53 is disabled, but also in maintaining cell cycle
arrest. Concomitantly, cell cycle and replication proteins such as
Cyclin A, MCM7 and PCNA are nearly undetectable in RB-
proficient cells after a prolonged exposure to CDDP, while these
same proteins are detected at equal levels in RB-deficient cells
under the same treatment (Figure 2A, right panel). Furthermore,
RB-proficient p53DD cells displayed a senescent-like morphology
as early as 2 days after exposure to CDDP, while RB-deficient cells
grew uninhibited in the presence of CDDP (Figure 2B, left panel).
As a direct test of cellular senescence, RB-proficient cells displayed
a 4- to 5-fold increase in b-galactosidase staining over both the
untreated control cells and the RB-deficient cells in the absence or
presence of CDDP (Figure 2B, right panel).
RB and p53 in Therapy Response
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responsible for the maintenance of cell cycle arrest, RB-proficient
p53DD cells were exposed to CDDP for 4 days, resulting in
significant cell cycle arrest and appearance of senescent cells.
These cells were then infected with Cre recombinase-encoding
adenoviruses to delete Rb. Upon Rb deletion, cells escaped from
cell cycle arrest and began replicating at levels equivalent to the
original untreated cell population (Figure 2C, left panel).
Correspondingly, levels of cell cycle and replication proteins were
dramatically enhanced (Figure 2C, right panel). Thus, these
studies indicate that RB status is not only required for the initiation
of cell cycle arrest by DNA damaging agents, but RB actively
participates in the maintenance of such cell cycle withdrawal in the
presence of a disabled p53 pathway.
RB-Deficiency Promotes Aggressive Recovery from
Therapy-Induced Damage and Dramatic Alterations in
Gene Expression
To evaluate the ability of cells deficient in RB and/or p53 to
recover from therapy-induced damage, cells were treated with
CDDP for 24 h and then allowed to recover in fresh media
without CDDP. Initial recovery experiments were performed with
six independently treated cell populations (Figure 3A), and all
subsequent assays were preformed with a minimum of two
independent, recovered cell populations. Two weeks post-CDDP
exposure, RB-proficient p53DD cells slowly recovered from
treatment and resumed proliferation (Figure 3A). In contrast,
RB-deficient p53DD cells recovered faster and very aggressively
from treatment, forming cell foci with a density ,3-fold greater
than that of the RB-proficient cells, as determined by intensity of
crystal violet staining (Figure 3A). Upon further evaluation of the
recurred, RB- and/or p53-deficient cell populations, the RB-
deficient, recurred cells grew ,3–4 times faster than the recurred,
RB-proficient cells, and with twice the kinetics of the naı ¨ve, RB-
deficient cells (Figure 3B, left panel). Interestingly, the enhanced
growth rate did not correspond to increased levels of cell cycle
and/or replication proteins (Figure 3B, right panel), indicating that
cell characteristics beyond those directly mediated by the RB
pathway may have been altered.
To define the basis of the aforementioned changes in cell
growth, gene expression profiling of each cell population was
determined using the Affymetrix GeneChip Mouse Genome 430
2.0 Array. Gene expression values were normalized to the RB-
proficient p53DD, untreated cells (GFP Naı ¨ve), and significant
changes in gene expression were determined using a 1.5-fold cut-
off and a FDR of ,25%. These data are displayed as a heat map
in Figure 3C (left panel). Only modest changes in gene expression
were observed between the RB-proficient and RB-deficient
p53DD, untreated cells, which were not significant based on the
aforementioned statistics. Similarly, comparison of the RB-
proficient, naı ¨ve and recurred cells (GFP Recurred vs. GFP
Naı ¨ve) indicated relatively modest alterations in gene expression.
In contrast, the RB/p53-deficient cells that had been treated with
CDDP (Cre Recurred) displayed dramatic alterations in gene
expression not observed in any other cell population (Figure 3C).
Gene ontology analyses did not identify a single key pathway
altered in these cell populations. However, the genes that were
significantly modified in this population included those previously
shown to suppress transformation (Figure 3C, top right panel)
[39,40,41,42,43]. Additionally, the RB-deficient p53DD, recurred
cells exhibited alterations in gene expression that were in accord
with a recently described signature of cooperative transformation
(Figure 3C, bottom right panel) [44]. Thus, CDDP damage, in the
absence of RB and p53, yielded a complex gene expression
Figure 1. Characterization of RB/p53 cooperation in cell
growth and acute DNA damage response. (A) Mouse adult
fibroblasts isolated from Rb
loxP/loxP mice were infected with adenoviral
GFP or GFP-Cre. Recombination was examined by PCR using primer
sequences flanking Rb exon 19. MAFs were subsequently infected with
retroviruses encoding LXSN or LXSN-p53DD. Cells were treated with
8 mM CDDP for 24 h, and total protein lysates were immunoblotted for
p53 and p21. Lamin B served as a loading control. (B) Cells were
cultured in normal growth media, pulsed with BrdU for 1 h prior to
harvesting, stained with FITC-anti-BrdU and PI and analyzed by flow
cytometry. Average percent BrdU incorporation is shown. **p,0.0054,
***p,0.0002 (C) Cells were cultured in normal growth media and viable
cells were counted every 24 h. ***p,0.0001 (D) Cells were treated with
4o r8mM CDDP for 24 h, pulsed with BrdU for 1 h prior to harvesting,
stained with FITC-anti-BrdU and PI, and analyzed by flow cytometry.
Average percent BrdU incorporation relative to untreated controls is
shown. ***p,0.0001.
doi:10.1371/journal.pone.0008558.g001
RB and p53 in Therapy Response
PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8558Figure 2. RB status mediates cell growth vs. senescence in response to chronic therapy-induced damage, independent of p53
status. (A) Cells were treated with 0.5 mM CDDP for 4 days. Cells were treated with 0.5 mM CDDP for 24 h, pulsed with BrdU for 1 h prior to
harvesting, stained with FITC-anti-BrdU and PI, and analyzed by flow cytometry. Top, representative traces for both PI and BrdU staining are shown.
Left, average percent BrdU incorporation relative to untreated controls is shown. ***p,0.0001 Right, total protein lysates were immunoblotted for the
indicated proteins. Lamin B served as a loading control. (B) Left, cells were cultured in 0.5 mM CDDP, and viable cells were stained with crystal violet.
Right, cells were treated with 0.5 mM CDDP for 2 days and stained for b-gal activity. Fold-increase in b-gal activity relative to untreated controls is
shown. ***p,0.0001 (C) Four days post-CDDP exposure, RB-proficient cells were subjected to adenoviral infection to delete Rb. Left, four days post-
infection, cells were pulsed with BrdU for 1 h prior to harvesting and processed as described in (A). Right, total protein lysates were prepared at each
time point for immunoblot analysis. Lamin B served as a loading control.
doi:10.1371/journal.pone.0008558.g002
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Cells were treated with 1 uM CDDP for 24 h, allowed to recover in fresh media, and stained with crystal violet two weeks post-treatment. Relative
staining intensities from six independent experiments were quantified. ***p,0.0001 (B) Left, cells were cultured in normal growth media, and viable
cells were counted over a course of 5 days. ***p,0.0001 Right, total protein lysates were immunoblotted for the indicated proteins. Lamin B served as
a loading control. (C) Gene expression data was averaged for each cell line and normalized to the RB-proficient p53DD, untreated cell population
(GFP Naı ¨ve). Left, changes in gene expression are displayed as a heat map. Right, those genes with specific involvement in transformation are
highlighted in bar graphs. Gene expression values are displayed as fold-change in gene expression.
doi:10.1371/journal.pone.0008558.g003
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oncogenic phenotype.
RB-Deficiency Promotes Alterations in Epigenetic
Programming, Resulting in Enhanced Cell Growth
To determine the underlying mechanism behind the dramatic
alterations in gene expression observed in the RB-deficient
p53DD, recurred cells, we first examined the locations of the
gene changes across the mouse genome. The dramatic (.50 fold)
down-regulation in specific genes displayed in the microarray data
indicated potential deletions of chromosome regions. However,
upon examining the overall distribution of gene changes across the
mouse genome, it was apparent that the gene alterations were
located throughout the genome and not the necessarily reflective
of a localized event (Figure 4A). These data lead us to examine the
Figure 4. RB loss promotes alterations in epigenetic programming. (A) Gene expression data for the RB-deficient p53DD, recurred cells
demonstrated by microarray analysis were mapped along the mouse genome, indicating locations of up-regulated (Red) and down-regulated (Blue)
genes. (B) Cells were cultured in the absence or presence of 5-aza-dC for 5 days, and RT-PCR was carried out for the indicated genes. (C) Cells were
cultured in the absence or presence of 5-aza-dC for 5 days, and viable cells were counted. ***p,0.0001.
doi:10.1371/journal.pone.0008558.g004
RB and p53 in Therapy Response
PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8558possibility that epigenetic alterations were behind the dramatic
gene down-regulation. In order to determine whether the changes
in gene expression observed in the RB-deficient p53DD, recurred
cells were the result of alterations in methylation, cells were treated
with 5-aza-29-deoxycytidine (5-aza-dC). First, RT-PCR was
performed to validate the gene expression profiles of a panel of
genes in each RB-proficient and RB-deficient, naı ¨ve and recurred
cell population (Figure 4B, left panel). Then, the RB-deficient
p53DD, recurred cells were treated with 5-aza-dC for 5 days, and
gene expression was re-examined. In the panel of genes examined,
5-aza-dC treatment resulted in restoration of expression of those
genes that were significantly down-regulated in the RB-deficient,
recurred cell population (Figure 4B, right panel). Interestingly,
genes that were up-regulated in the RB-deficient, recurred cells
displayed varying responses to 5-aza-dC treatment. For example,
while Gpr149 expression was sensitive to 5-aza-dC treatment,
Pla2g7 expression was unaltered (Figure 4B, right panel). Taken
together, these data indicate that, at least for these genes that were
down-regulated in the RB-deficient p53DD, recurred cells,
changes in epigenetic programming represent a key mechanism
behind the altered gene expression profile observed.
To determine whether such epigenetic alterations were
responsible for the enhanced growth characteristics of the RB-
deficient p53DD, recurred cell population, cell growth was
examined after 5 days of 5-aza-dC treatment. The RB-deficient,
recurred cells displayed a significantly decreased growth rate as a
result of 5-aza-dC treatment (Figure 4C). Furthermore, the RB-
proficient, naı ¨ve and recurred cells, as well as the RB-deficient,
naı ¨ve cells, were unaffected by 5-aza-dC treatment. These data
indicated that the enhanced growth characteristics observed in the
RB-deficient, recurred cells were the result of a dramatic
deregulation of gene expression caused by alterations in epigenetic
programming.
RB-Deficiency and Response to Therapy-Induced
Damage Results in a Tumorigenic Cell Population
Based on these findings, we directly interrogated the tumori-
genic properties of both naı ¨ve and recurred cell populations.
Initially, the overall morphology of the cells, as determined by
phalloidin staining, indicated significant remodeling of actin fibers,
similar to that observed in Ras-transformed cells (Figure 5A). To
further assess the potential transformation of these cells, RB-
proficient and RB-deficient p53DD, naı ¨ve and recurred cells were
challenged first by growth under anchorage independent condi-
tions. The RB-deficient p53DD, recurred cells displayed a
significantly enhanced growth rate in comparison to the other
cell populations (Figure 5B, left panel), which was accompanied by
deregulated ERK signaling, as demonstrated by increased levels of
phosphorylated ERK, and an up-regulation of proliferative
proteins such as cyclin D1 and cyclin A (Figure 5B, right panel).
Furthermore, upon injection into the flanks of nude mice, only the
RB-deficient p53DD, recurred cells were able to initiate tumor
formation over the indicated time course (Figure 5C, top panel).
Neither inactivation of p53 function alone, nor combined
inactivation of RB and p53 resulted in tumor development.
Similarly, the RB-proficient p53DD, recurred cells were incapable
of forming tumors (Figure 5C, top panel). In contrast, injection of
the RB-deficient p53DD, recurred cells resulted in the formation
of tumors displaying significant cytological abnormalities. These
tissues exhibited distinct nuclear pleomorphisms, nuclear inclu-
sions, and high mitotic indexes, indicative of an undifferentiated
sarcoma (Figure 5C, bottom panel).
Taken together, these findings indicate that RB is a critical
suppressor of cellular transformation and tumorigenesis following
therapy-induced damage, independent of p53 status. Furthermore,
RB loss in the presence of therapy-induced damage can result in
dramatic evolution of cells that can have significant impact on
tumorigenesis not observed through loss of tumor suppressors
alone.
RB-Deficient Recurred Cells Display Enhanced Resistance
to Discrete Therapeutic Challenges
Many cancer models have been shown to develop resistance to
therapy [45]. As the loss of RB was observed to promote
tumorigenesis after recovery from therapy-induced damage, the
response of this cell population to subsequent treatment was
evaluated. Both naı ¨ve and recurred, RB-proficient p53DD cells
exhibited a significant decrease in replication upon treatment with
CDDP (Figure 6A). Similar to previous results, naı ¨ve, RB-deficient
cells were able to significantly bypass the DNA damage checkpoint
compared to RB-proficient cells, though still displaying some
sensitivity. Interestingly, RB-deficient p53DD cells that have
recovered from an initial treatment of CDDP were more resistant
to a second treatment, as compared to all other cell lines
(Figure 6A), and the ability of the RB-deficient p53DD, recurred
cell population to continue proliferating post-CDDP treatment
was enhanced (Figure 6B). One potential reason for the differences
in sensitivity to CDDP is related to an alteration in cellular uptake
of the DNA damaging agent. As such, CDDP-adduct formation
was examined within the cells by immunofluorescence. There was
no significant difference in CDDP-adduct formation in any of the
cell lines tested (Figure 6C). Thus, the differences in sensitivity to
CDDP treatment observed between the cell lines are not due to
variations in CDDP damage, but instead must be attributed to a
difference in cellular response to the damage. To determine
whether these findings represented a multi-drug resistance
phenotype or specific resistance to CDDP, the cell populations
were challenged with additional therapeutic agents. Interestingly,
all cell populations displayed sensitivity to etoposide or campto-
thecin treatments (Figure 6D). However, RB-deficient p53DD,
recurred cells displayed a resistance to mitomycin C treatment that
was comparable to the CDDP resistance phenotype and not
observed in any of the other cell lines (Figure 6D). Combined,
these data indicate that loss of RB facilitates not only the
transformed phenotype, but resistance to subsequent challenge
with discrete therapeutic agents.
Discussion
Cancer is one of many diseases that arise from multiple genetic
and epigenetic alterations within a cell [2,46,47,48]. Here, we
dissected how two commonly inactivated tumor suppressors
function in the response to therapy-induced damage and
examined the consequence of such challenge in terms of oncogenic
behavior and therapeutic resistance.
At a molecular level, the RB and p53 pathways intersect at
multiple points that have implications for the behavior of tumors
harboring distinct combinations of tumor suppressor pathway
aberrations [18,20]. Critically, these tumor suppressor pathways are
key modulators of stress signals and represent an important barrier
to tumorigenesis. Loss of RB and p53 has lead to enhanced tumor
susceptibility in various cell types and mouse models in response to
DNA damaging agents, demonstrating the importance of RB and
p53 in mediating cellular response to exogenous stress [49,50,51].
Additionally, studies examining oncogene activation have indicated
that certain types of endogenous stresses are capable of inducing
DNA damage and subsequent p53 inactivation [52]. Loss if p53
function in this setting leads to genomic instability, which promotes
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been shown to elicit a damage response [53]. Furthermore, there
are numerous additional endogenous stress signals, including
metabolic, oxidative and mitotic stresses, which are characteristic
of cancers and thought to be tolerated by cancer cells through
inactivation of tumor suppressor pathways [54]. Thus, tumor
suppressor pathways, such as the RB and p53 pathways, are critical
for mediating cellular response to both exogenous and endogenous
stress signals, and inactivation of these pathways paves the way for
cancer development.
Figure 5. RB-deficiency and response to therapy-induced damage promotes tumorigenesis. (A) Asynchronously growing cells were
stained with phalloidin. Ras transformed cells are representative of transformed morphology. (B) Left, cells were cultured in non-coated Petri dishes,
and viable cells were counted over a course of 6 days. ***p,0.0001 Right, total protein lysates were immunoblotted for the indicated proteins. Lamin
B served as a loading control. (C) Top, Cells were injected into the flanks of nude mice, and tumor volumes were measured every 7 days post-palpable
tumor formation. ***p=0.0003 Bottom, representative H&E stained tissue sections of Cre p53DD, recurred xenografts are shown.
doi:10.1371/journal.pone.0008558.g005
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dominant-negative strategy yielded a similar effect on the
expression of genes that are regulated by the E2F family of
transcription factors. This result is consistent with prior studies that
show similar gene expression programs are regulated by these
pathways in microarray analyses [14,55]. In further keeping with
these results, microarray analyses carried out in cells harboring the
dominant negative p53 allele indicated little effect of RB deletion
on gene expression programs in the absence of extrinsic stress.
While overall these findings suggest that RB and p53 function in
an overlapping pathway, there was a striking dependency on RB
for the cell cycle inhibitory response to cisplatin. This role for RB
was evident both in the context of acute and chronic exposures, a
finding that is highly reflective of studies performed in human
tumor models that suggest RB status is dominant to p53 status in
determining cell cycle inhibition upon exposure to genotoxic
therapeutic agents [25,26]. Importantly, in the setting of chronic,
low dose cisplatin exposure, there was a dramatic reduction in
E2F-regulated targets, an effect that was singularly dependent on
the presence of RB. In such conditions, RB-proficient cells
establish a seemingly permanent growth arrest that is indicative of
cellular senescence. By employing targeted deletion of RB in these
populations, it was demonstrated that loss of RB is not only
necessary for the initiation of this state, but also for its
maintenance. Combined, these findings indicate that even in the
presence of compromised p53 function, RB plays important roles
in mediating specific cellular and molecular responses to DNA
damage.
The composite loss of RB and p53 function is observed in
multiple settings associated with cancer. For example, DNA tumor
viruses have evolved key mechanisms that abrogate both tumor
suppressor pathways in the same infected cell [56]. Here we
investigated the dual influence of dysregulation of these key tumor
suppressors in the context of oncogenic transformation. Interest-
ingly, although p53 plays a dominant role in proliferation, the loss
of RB was able to further accelerate the proliferation of such cell
populations in cell culture. In spite of this growth advantage, dual
RB/p53-deficient cells are not spontaneously transformed. For
example, there is minimal tumor growth from these cells in nude
mouse models. Thus, the transformed phenotype is a result of
additional lesions beyond loss of these tumor suppressors alone. As
shown here, cisplatin-mediated DNA damage can represent a key
cooperating factor leading to oncogenic transformation.
Prior studies have demonstrated that RB loss can alter DNA
ploidy in the presence of DNA damage, and tetraploid p53-
deficient cells can readily progress to an oncogenic phenotype
[57,58,59,60]. Therefore, it was surprising in our model that
minimal alterations in ploidy were observed, and there was no
clear evidence of gross chromosomal instability. However,
microarray analyses demonstrated significant changes in gene
expression, specifically in the RB-deficient cell population that had
recurred following CDDP treatment. Interestingly, these genes are
neither directly regulated by p53 or RB/E2F, nor are they direct
targets of acute DNA damage. Rather, a number of genes in this
complex program corresponded to previously published ‘‘cooper-
ation response genes’’ involved in a cooperative transformation
process involving p53 [44]. Furthermore, there was dramatic
down-regulation of a number of genes previously shown to be
involved in suppressing tumorigenesis in various models
[39,40,41,42,43]. This down-regulation was the result of alter-
ations in the epigenetic programming of the cells, indicating that
cooperative inactivation of the RB and p53 pathways can lead to
modifications in epigenetic signaling. Taken together, these data
suggest that the composite inactivation of RB and p53 has a
Figure 6. RB-deficiency promotes discrete therapeutic resis-
tance after recovery from therapy-induced damage. (A) Cells
were treated with 8 uM CDDP for 24 h, pulsed with BrdU for 1 h prior
to harvesting, and processed as described in Figure 1C. Average percent
BrdU incorporation relative to untreated controls is shown. **p=0.0024
(B) Cells were treated with 8 uM CDDP for 24 h, allowed to recover in
fresh media for 4 days, and viable cells were counted at indicated time
points. ***p,0.0001 (C) Cells were treated with 8 uM CDDP for 24 h
and stained for CDDP-adduct formation. Red, CDDP adducts; Blue, DNA
stained with DAPI. (D) Cells were treated with etoposide (Etop, 1 uM),
camptothecin (Cpt, 5 uM), or mitomycin C (MMC, 2 uM) for 24 h, pulsed
with BrdU 1 h prior to harvesting, and processed as described in
Figure 1C. Average percent BrdU incorporation relative to untreated
controls is shown. ***p,0.0001.
doi:10.1371/journal.pone.0008558.g006
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genetic rewiring that is indicative of cellular transformation. In
keeping with this concept, specifically RB-deficient, recurred cells
exhibited a transformed phenotype and were tumorigenic in
immune compromised mice.
Prior studies have implicated RB as playing a complex role in
the response to chemotherapeutic agents [8,25,26,27]. Upon
exposure to cytotoxic agents, RB loss is associated with a
predilection toward increased apoptotic death at a cellular level
and enhanced sensitivity in specific xenograft models
[25,26,27,35]. In fact, even in the presence of compromised p53
function, an initial sensitivity to the cytotoxic effects of cisplatin in
cells lacking RB was observed. However, under the low/clinically
relevant doses utilized herein, viable cells uniformly escaped this
treatment. We believe that this is significant, as recurrence
following treatment with conventional cytotoxic chemotherapies is
a well-established clinical problem. A striking characteristic of RB-
deficient cells in response to CDDP is their failure to undergo a
senescent-like cell cycle arrest. This finding has implications for
therapeutic response, wherein the establishment of senescence has
been associated with improved response to therapeutic approaches
[61], and suggests that somatic loss of RB in tumors could
contribute to ultimate tumorigenic outgrowth of the cell
population. Importantly, it has been observed that Rb gene
dosage has a significant impact on susceptibility to secondary
malignancies induced by DNA damage (i.e. ionizing radiation)
[30]. Thus, this pathway could also be relevant in the context of
therapy-induced malignancies. Tumors that recur post-therapy are
often exceedingly aggressive and resistant to subsequent thera-
peutic interventions. As shown here, the oncogenic behavior of
cells lacking RB was particularly aggressive and exhibited
resistance to subsequent rounds of cisplatin and mitomycin C
treatment, but not treatment with etoposide or camptothecin.
Thus, RB status could be an important determinant in directing
treatment regimens for both primary and recurred malignancies.
Combined, these findings indicate that RB-deficient tumors are
prone to significant evolution during therapeutic challenge, and
reveal an additional mechanism by which RB loss promotes
disease progression. Further studies investigating the impact of
distinct environmental and therapeutic stresses on tumor suppres-
sor pathways are beginning to reveal key facets of both tumor
etiology and treatment response. Such analyses hold the promise
of understanding both mechanisms to limit cancer progression and
to more effectively intercede in clinical treatment.
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